AbbVie Inc.
ABBV
$146.28
-$1.12-0.76%
| Weiss Ratings | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Excellent | |||
| Risk Index | Fair | |||
| Risk Grade | C+ | |||
| Reward Grade | A+ | |||
| Rating Factors | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Good | |||
| Growth Index | Excellent | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Good | |||
| Total Return Index | Good | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.27 | |||
| Price History | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.63% | |||
| 30-Day Total Return | -10.43% | |||
| 60-Day Total Return | 0.52% | |||
| 90-Day Total Return | 5.22% | |||
| Year to Date Total Return | -9.06% | |||
| 1-Year Total Return | 10.10% | |||
| 2-Year Total Return | 52.51% | |||
| 3-Year Total Return | 99.86% | |||
| 5-Year Total Return | 51.20% | |||
| 52-Week High % Change | -16.84% | |||
| 52-Week Low % Change | 9.94% | |||
| Price | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $175.91 | |||
| 52-Week Low Price | $133.05 | |||
| 52-Week Low Price (Date) | Feb 02, 2022 | |||
| 52-Week High Price (Date) | Apr 08, 2022 | |||
| Valuation | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | $258.61B | |||
| Enterprise Value | 316.76B | |||
| Price/Earnings (TTM) | 19.50 | |||
| Earnings Per Share (TTM) | 7.50 | |||
| Earnings Per Share Growth | 78.66% | |||
| Price/Earnings To Growth | 0.25 | |||
| Price/Sales (TTM) | 4.49 | |||
| Price/Book (Q) | 16.17 | |||
| Enterprise Value/Revenue (TTM) | 5.48 | |||
| Price | $146.28 | |||
| Enterprise Value/EBITDA (TTM) | 10.61 | |||
| Enterprise Value/EBIT | 14.68 | |||
| Market Cap Category | Mega Cap | |||
| Dividends and Shares | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.776B | |||
| Dividend Yield | 3.90% | |||
| Div. Per Share (Most Recent) | $1.48 | |||
| Dividend Per Share (TTM) | $5.71 | |||
| Payout Ratio (TTM) | 73.48% | |||
| Dividend Per Share (Most Recent) | $1.48 | |||
| Company Info | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 847 932 7900 | |||
| Address | 1 North Waukegan Road North Chicago, IL 60064-6400 | |||
| Website | www.abbvie.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 37.31% | |||
| Profit Margin | 23.18% | |||
| Management Effectiveness | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 9.29% | |||
| Return on Equity | 90.65% | |||
| Income Statement | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | $57.82B | |||
| Total Revenue (TTM) | $57.82B | |||
| Revenue Per Share | $32.56 | |||
| Gross Profit (TTM) | $40.38B | |||
| EBITDA (TTM) | $29.86B | |||
| EBIT (TTM) | $21.57B | |||
| Net Income (TTM) | $13.41B | |||
| Net Income Avl. to Common (TTM) | $13.41B | |||
| Total Revenue Growth (Q YOY) | 3.28% | |||
| Earnings Growth (Q YOY) | 24.28% | |||
| EPS Diluted (TTM) | $7.50 | |||
| EPS Diluted Growth (Q YOY) | 24.16% | |||
| Balance Sheet | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | $11.88B | |||
| Cash Per Share (Q) | $6.69 | |||
| Total Current Assets (Q) | $30.36B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | $16.03B | |||
| Current Ratio (Q) | 0.928 | |||
| Book Value Per Share (Q) | $9.04 | |||
| Total Assets (Q) | $141.33B | |||
| Total Current Liabilities (Q) | $32.71B | |||
| Total Debt (Q) | $70.00B | |||
| Total Liabilities (Q) | $125.30B | |||
| Total Common Equity (Q) | $15.99B | |||
| Cash Flow | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -$1.32B | |||
| Cash from Financing (TTM) | -$21.51B | |||
| Net Change in Cash (TTM) | -$350.00M | |||
| Levered Free Cash Flow (TTM) | $20.24B | |||
| Cash from Operations (TTM) | $22.59B | |||
